Zoetis Inc  

(Public, NYSE:ZTS)   Watch this stock  
Find more results for ZTS
65.58
+0.02 (0.03%)
After Hours: 65.53 -0.05 (-0.08%)
Oct 19, 4:11PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 65.16 - 65.69
52 week 46.86 - 66.11
Open 65.50
Vol / Avg. 1.57M/1.98M
Mkt cap 32.08B
P/E 37.04
Div/yield 0.10/0.64
EPS 1.77
Shares 489.11M
Beta 1.03
Inst. own 97%
Nov 7, 2017
Zoetis Inc at Credit Suisse Healthcare Conference - 11:30AM EST - Add to calendar
Nov 2, 2017
Q3 2017 Zoetis Inc Earnings Release - 9:30AM EDT - Add to calendar
Nov 2, 2017
Q3 2017 Zoetis Inc Earnings Call - 8:30AM EDT - Add to calendar
Sep 26, 2017
Zoetis Inc at Cantor Fitzgerald Global Healthcare Conference - Webcast
Aug 8, 2017
Q2 2017 Zoetis Inc Earnings Release
Aug 8, 2017
Q2 2017 Zoetis Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Jul '17) 2016
Net profit margin 19.46% 16.76%
Operating margin 27.19% 25.12%
EBITD margin - 34.31%
Return on average assets 12.82% 10.53%
Return on average equity 59.61% 64.27%
Employees 9,000 -
CDP Score - -

Address

10 Sylvan Way
PARSIPPANY, NJ 07054-3825
United States - Map
+1-973-8227000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Officers and directors

Juan Ramon Alaix Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Glenn David Chief Financial Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Roxanne Lagano Chief Human Resource Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Andrew Fenton Executive Vice President, Chief Information Officer
Age: 52
Bio & Compensation  - Reuters
Heidi C. Chen Executive Vice President, General Counsel, Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Alejandro Bernal Executive Vice President, Group President - Strategy, Commercial and Business Development
Age: 44
Bio & Compensation  - Reuters
Catherine A. Knupp Executive Vice President, President - Research and Development
Age: 56
Bio & Compensation  - Reuters
Clinton A. Lewis Jr. Executive Vice President, President - International Operations
Age: 51
Bio & Compensation  - Reuters
Kristin C. Peck Executive Vice President, President - U.S. Operations
Age: 46
Bio & Compensation  - Reuters
Roman Trawicki Executive Vice President, President of Global Manufacturing and Supply
Age: 53
Bio & Compensation  - Reuters